Pancreatic Cancer Extreme Drug Resistance
Learn More About Pancreatic Cancer Extreme Drug Resistance Assay: Chat with Us | Email Us
Pancreatic Cancer: Extreme Drug Resistance
The Extreme Drug Resistance (EDR) Assay (or chemoresistance test) is another innovative way CTCA tailors a pancreatic cancer treatment plan for each patient fighting pancreatic cancer.
The EDR is a highly accurate test that determines the probability of a solid tumor’s resistance to specific chemotherapeutic drugs. If the cancerous pancreatic cells multiply in the presence of extreme exposure to a drug, it indicates significant resistance to that drug. If the tumor is resistant to a drug in this assay, then the tumor growing in a patient’s body will almost certainly be resistant to that drug.
This information allows your CTCA physicians to avoid unnecessary toxicity, consider other pancreatic cancer treatment protocols, and minimize costs.
Next Topic: MRI for Pancreatic Cancer
